0001104659-26-032063
SEC filingMustang Bio, Inc. (MBIO), a clinical-stage biopharmaceutical company, reported a significantly reduced net loss of $1.9 million for FY 2025, compared to $15.8 million in FY 2024, driven by lower research and development expenses of $1.5 million (down from $8.4 million) due to settlements of aged payables ($2.1 million savings), lease termination gain ($0.4 million), and reduced clinical and sponsored research costs. No revenue was generated, consistent with pre-commercial status and no approved products. Operating loss narrowed to $2.4 million from $16.2 million, reflecting cost reductions including no asset impairment (vs. $3.7 million prior year) and lower general/administrative expenses. Cash and cash equivalents rose to $17.3 million from prior levels, bolstered by $14.5 million net financing inflows (equity offerings and warrant exercises) offsetting $5.3 million operating cash use and supported by $1.2 million investing proceeds from equipment sale. Total assets stood at $17.6 million, with stockholders' equity at $9.5 million. Accumulated deficit was $398.6 million. Forward-looking, the company believes cash suffices for at least 12 months, focusing on MB-101, MB-108, and MB-109 pipeline advancement toward potential 2026 trials, amid ongoing funding needs.
Mustang Bio reported a net loss of $1.9 million for FY 2025, a substantial improvement from $15.8 million in FY 2024, primarily due to reduced R&D expenses ($1.5 million vs. $8.4 million) from $2.1 million payables settlements, $0.4 million lease termination gain, and lower clinical/sponsored research costs. No asset impairment was recorded (vs. $3.7 million prior year). Operating loss decreased to $2.4 million from $16.2 million. G&A expenses slightly declined to $3.9 million from $4.1 million. Balance sheet strengthened with total assets at $17.6 million, cash $17.3 million, liabilities $8.1 million, and equity $9.5 million. Cash flow showed $5.3 million operating use, $1.2 million investing inflow, and $14.5 million financing proceeds, yielding $10.4 million net cash increase.
No revenue generated in FY 2025 or 2024, as the company remains pre-revenue with no approved products. Pipeline focused on MB-101 (CAR T), MB-108 (oncolytic virus), and MB-109 combination for brain tumors, with ongoing investigator-sponsored trials and potential Q2 2026 start. No segment breakdowns disclosed.
Pre-revenue status precludes gross/operating margins. Net loss per share not specified. Cost structure improved via payables settlements ($2.1 million R&D credit), workforce reduction, and facility lease terminations. R&D dominated expenses but declined 118% YoY; G&A stable at 5% decrease.
Operating cash use $5.3 million (net loss $1.9 million, adjusted for non-cash items). Investing $1.2 million inflow from equipment sale. Financing $14.5 million from equity offerings ($6.8 million), ATM ($0.6 million), warrants ($7.1 million). Ending cash $17.3 million supports 12+ months runway. Current liabilities $7.9 million; no long-term debt noted.
Management states sufficient cash for 12 months post-filing, no going concern doubt. Priorities: advance MB-109 Phase 1 potentially Q2 2026 under COH IND; leverage FDA Orphan Drug Designations for MB-101/MB-108. Risks include funding needs, clinical delays, reliance on partners (COH, Nationwide), and Nasdaq compliance. No quantitative guidance provided.